UEG Podcast

Around half of patients with pancreatic cancer are diagnosed after the disease has already spread. Dr Pilar Acedo Nuñez from UCL joins Eglė Dieninytė to discuss screening and why we still rely on CA 19-9, what the new RAS inhibitors could mean for patients, whether molecular profiling should be routine, and what the first-in-human KRAS vaccine trial has shown in people at high risk of pancreatic cancer. Part 2 will look at treatment options.

Rome V was published ten years after Rome IV. Maura Corsetti, co-chair of the Rome V Bowel Disorders committee, joins Pradeep Mundre to discuss the relaxed IBS criteria, three new adult diagnoses, the split between research and clinical criteria, and why explaining a gut-brain diagnosis early spares patients repeat investigation.

Flares, surgery and the postpartum period. Mette Julsgaard and Pradeep Mundre on whether active disease or a JAK inhibitor is the bigger risk, starting upadacitinib at 28 weeks, acute severe colitis and when to operate, vaccinating infants exposed to biologics.

Mette Julsgaard and Pradeep Mundre on IBD before and during pregnancy: what active disease costs in fertility, what to check at the preconception visit, and a drug by drug run through of what to stop, continue and start, from 5-ASAs and thiopurines to biologics and JAK inhibitors, as well as the use of low-dose aspirin.

Operate on every high-risk early oesophageal cancer after endoscopic resection and more than 80% of those patients gain nothing. Roos Pouw, Ana-Maria Bucalau and Jessie Elliott on strict endoscopic follow-up, the shift from chemoradiation to perioperative FLOT, and what ENSURE showed about surveillance after oesophagectomy.